ArticleAnnals of Indian Academy of Neurology2026
A Study on Protocol-based Treatment Change in Drug-resistant Epilepsy Patients in a Tertiary Care Center in Eastern India.
Article in Annals of Indian Academy of Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesManagement of drug-resistant epilepsy (DRE) remains challenging. A considerable subset of such patients who cannot access nonpharmacological treatment options relies on antiseizure medication (ASM) combination therapy, for which no standardized guidelines currently exist. This study aimed to determine the efficacy of treatment changes using a clinic-based strategic treatment protocol in patients with DRE. Furthermore, it sought to identify clinical factors associated with a positive patient response to these adjustments.
methodsWe conducted a prospective observational study including 138 patients with DRE who were followed for 24 months. Seizure frequency was assessed at 3, 6, and 12 months.
resultsA total of 469 drug-changing interventions were performed across the cohort (284 for focal epilepsy and 185 for generalized and unknown seizures). Key findings included: (1) Seizure reduction: Univariate analysis revealed a statistically significant reduction in seizure frequency at the 3-, 6-, and 12-month follow-ups (22% and 41% reduction at 6 and 12 months, respectively; P = 0.0146, P = 0.0014, and P = 0.0001, respectively). (2) Predictive factors: Multivariate analysis demonstrated that age at disease onset, disease duration, and number of ASMs prescribed both before the index date and at 6 and 12 months were statistically significant predictors of therapeutic response ( P < 0.05). (3) Remission rates: At the 12-month follow-up after rescheduling, 19.56% (n = 27) of patients achieved complete seizure freedom.
conclusionsModifying ASM regimens through a strategic protocol yielded significant improvements in seizure control in patients with DRE during the one-year follow-up period. Clinical and treatment-related factors independently predicted outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.